Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147,179,178
-
Total 13F shares
-
70,718,085
-
Share change
-
-575,615
-
Total reported value
-
$1,231,893,094
-
Put/Call ratio
-
127%
-
Price per share
-
$17.42
-
Number of holders
-
106
-
Value change
-
-$9,090,266
-
Number of buys
-
40
-
Number of sells
-
50
Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q4 2019
As of 31 Dec 2019,
Denali Therapeutics Inc. - COMMON STOCK (DNLI) was held by
106 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
70,718,085 shares.
The largest 10 holders included
Crestline Management, LP, Flagship Pioneering Inc., BAILLIE GIFFORD & CO, VANGUARD GROUP INC, BlackRock Inc., Temasek Holdings (Private) Ltd, FMR LLC, STATE STREET CORP, Casdin Capital, LLC, and WASATCH ADVISORS INC.
This page lists
107
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.